PFE · 8-K · 20260804PR000094
Capital Return Program
PFIZER INC · 2026-08-04 · Importance 37 · Surprise 6 · In source text
Pfizer paid $4.9 billion of cash dividends during the first six months of 2026, equal to $0.86 per common share. The company invested $5.3 billion in internal R&D projects and approximately $170 million in business development transactions during the same period. No share repurchases had been completed in 2026 as of August 4, and the remaining repurchase authorization was $3.3 billion. Current 2026 financial guidance assumes no share repurchases while Pfizer continues to delever its balance sheet.
Key facts
- No share repurchases have been completed to date in 2026 and remaining share repurchase authorization as of August 4, 2026: $3.3 billion; current guidance does not anticipate any share repurchases in 2026 source
- Pfizer returned $4.9 billion of cash dividends in the first six months of 2026, or $0.86 per share source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | realized | — | Pfizer returned $4.9 billion of cash dividends in the first six months of 2026, or $0.86 per share |